Ekso Bionics’ (EKSO) “Buy” Rating Reiterated at HC Wainwright

Ekso Bionics (NASDAQ:EKSO)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $9.00 target price on the stock.

A number of other analysts also recently issued reports on EKSO. Lake Street Capital decreased their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. StockNews.com started coverage on Ekso Bionics in a research note on Tuesday. They issued a “hold” rating on the stock.

Ekso Bionics Trading Down 6.4 %

Shares of Ekso Bionics stock opened at $0.65 on Tuesday. The stock has a fifty day moving average price of $0.69 and a 200-day moving average price of $0.95. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The firm has a market cap of $14.30 million, a PE ratio of -1.00 and a beta of 1.47. Ekso Bionics has a 1 year low of $0.50 and a 1 year high of $2.50.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The company had revenue of $4.13 million during the quarter, compared to the consensus estimate of $6.00 million. During the same period in the prior year, the firm posted ($0.24) EPS. Equities research analysts anticipate that Ekso Bionics will post -0.48 EPS for the current year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.